SALT LAKE CITY--(BUSINESS WIRE)--Great Basin Corporation, a privately-held molecular diagnostics company developing sample-to-result solutions, announced today that a study published in the July issue of the Journal of Clinical Microbiology demonstrates its TB ID/R assay to be 96 percent accurate in detecting rifampin-resistant Mycobacterium tuberculosis (TB). The assay is currently under development to provide rapid diagnosis and drug susceptibility information for TB.
